There is a great deal of uncertainty in the orthopedic market as the world struggles with the COVID-19 pandemic. The situation will remain fluid for a significant period of time, which leads us to advise that the real impact of the virus on the orthopedic chain will not be clear until 2021 or even later.

After consulting with a host of industry veterans and observers, our guidance recommends that you expect and plan for business disruptions and revenue declines across the board—all companies, across all market segments. In the same breath, we’re confident that the orthopedic market will recover due to demographics and the lasting economic need to keep us all productive.
While AAOS’ Annual Meeting won’t go on as planned, important conversations will continue to take place. This issue of the newsletter is dedicated to trends we expected to hear about in Orlando. 

We asked Annual Meeting Committee Chair Andrew H. Schmidt, M.D., to weigh in on the technology topics of utmost importance to the orthopedic community. “In 2020, the AAOS is initiating a significant investment in the field of biologics, which many surgeons view as the next frontier in meeting many of the challenges of musculoskeletal health, such as preventing (rather than treating) osteoarthritis,” he said. “Other important areas of interest are in preventing device-related infection, continued innovation in less-invasive surgical approaches and adoption of new technologies such as robotics.”

The “wait and see” period for enabling technology in orthopedics is over. Commentary from executives and spending patterns of the largest companies affirmed that message in the first three months of 2020.

The joint replacement market surpassed $19 billion in 2019, +3% vs. 2018. The rapidly expanding importance of robotics and other enabling technologies drove growth of the knee and hip markets, while new shoulder systems pushed growth of the extremities market.

Members and 30-day Trial Members can access this 13-page report in the Download Zone.

The $122 million transaction is slated to close in 3Q20. EOS imaging provides orthopedic medical imaging and software solutions, such as rapid, low dose, biplanar full-body imaging and 3D modeling capabilities. The technology captures a full-body image in a weight-bearing position, allowing for precise measurement of anatomical angles and dimensions.

The completed transaction is expected to immediately expand ATEC’s revenue base, and create pull-through and cross-selling opportunities through an expanded sales network and combined customer base. EOS imaging will advance ATEC’s AlphaInformatiX platform providing capabilities in surgical planning, patient-specific implants, intraoperative alignment reconciliation and other intraoperative functionalities.

OrthoPediatrics will market Graftys® QuickSet bone cement in the U.S. under the tradename QuickPack™.

The product is delivered in a closed loop double-compartment syringe specifically designed for safety, reproducibility and ease-of-use, with no risk of preparation mistake and no product loss.

We’re full swing into 2020, our 20th anniversary of Membership, and we're excited to share that the new ORTHOWORLD.com will be available to you next month. The new site addresses your requests to zero in on the content you seek fast while using your preferred device.

Importantly, the look of your ORTHOFLASH® emails will change, but the content won’t. It will continue to be concise and free from ads and marketing hype—just how you like it.

Expect an email or two in the coming weeks with guidance for accessing the new site.

The figure includes 5,000 procedures assisted with the BalanceBot ligament balancing robot.

BalanceBot enables surgeons to balance knee joints using feedback from soft tissue and ligaments throughout the entire range of motion. It is employed in the Predictive Balance™ technique to predict the effect that implant positioning will have on knee gaps in flexion, extension and midflexion.

The imageless, open platform sprovides quantitative measurements of varus/valgus, flexion and slope angles, as well as resection depth to align cutting guides in the sagittal and coronal planes.

Mobi-C is the first cervical disc prosthesis approved by FDA for reconstruction of a cervical disc at one and two levels. The cobalt chromium alloy and polyethylene mobile-bearing device is inserted in a single step through an anterior approach, without bone chiseling or other vertebral anchorage.

In the race to capitalize on patient-driven interest in stem cells, biologic solutions and “regeneration” of a more vital, healthy and functional body, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence. Some believe that new regulatory guardrails, and a return to conscientious management of healthcare resources, will lead to more principled product promotion and patient care.

Aakash Agarwal, Ph.D., Director of Research at Spinal Balance, argues that the millions of reprocessed and exposed orthopedic devices in the field should be a significant focus for the industry.

“Every upcoming technology in the field of orthopedics focuses on precision and efficacy, with the intention to boost performance (healing) and safety,” he said. “Avoiding reprocessing and intraoperative exposure is the most obvious (and also most neglected) safety measure in the orthopedic industry. Fixing this problem will be a major leap toward patient safety.”

The company is addressing biological molecule diffusion through a synthetic nanoclay gel technology called Renovite. The injectable material stimulates the patient’s stem cells to generate new tissue. With time, it is entirely replaced by the newly-formed tissue at the exact location it was applied.
This eNewsletter is published by ORTHOWORLD Inc. and is available to Members of ORTHOWORLD or by email subscription . Copyright © 2020. All rights reserved.

Carolyn LaWell, Chief Content Officer | carolyn@orthoworld.com
Julie A. Vetalice, Editorial Assistant | julie@orthoworld.com